U.S. labelled-use references2026-10-17
Semaglutide is a peptide GLP-1 receptor agonist. It influences glucose regulation and appetite. The ingredient exists in different products, including injectable and oral formulations; their indications and instructions are not interchangeable.
- Route / discussion scope
- Subcutaneous injection; oral products also exist
- Conditions / goals discussed
- Type 2 diabetes · Obesity
SemaglutideType 2 diabetes / glucose control
Supports glucose-dependent insulin release.
An obesity-branded product is not an automatic substitute. Source ↗
SemaglutideObesity / selected overweight patients
Appetite effects support medically supervised weight management.
Eligibility is product- and patient-specific. Source ↗
Health goals & wellness limitsWeight treatment is structured medical care with nutrition, activity and follow-up. A weight-loss indication does not establish rejuvenation or longevity benefits in healthy people. Compounded products do not inherit FDA approval from a branded ingredient. [C2,C3]
Read the full guide & references →U.S. labelled-use references2026-10-17
Tirzepatide is a peptide that acts at GIP and GLP-1 receptors. Its metabolic actions connect diabetes, body weight and selected obesity-related conditions; this does not make it a universal health tonic.
- Route / discussion scope
- Subcutaneous injection
- Conditions / goals discussed
- Type 2 diabetes · Obesity · Obstructive sleep apnoea
TirzepatideType 2 diabetes
Acts through incretin pathways to help glucose regulation.
Match the product to the diabetes indication. Source ↗
TirzepatideChronic weight management
Reduces appetite and food intake.
Use within a wider medical care plan. Source ↗
Tirzepatide / ZepboundOSA with obesity: specific U.S. indication
Weight-related effects can improve this defined sleep-apnoea population.
Not a general replacement for sleep-apnoea assessment or devices. Source ↗
Health goals & wellness limitsMetabolic improvement is not proof of general anti-ageing benefit. Track the diagnosed condition and functional goals rather than using a lower weight as the sole definition of health. [C3]
Read the full guide & references →U.S. labelled-use references2026-10-17
Insulin medicines replace or supplement the action of a peptide hormone. Preparations differ in onset and duration. Human insulin and insulin analogues form a family of medicines rather than one interchangeable injection.
- Route / discussion scope
- Usually subcutaneous; some preparations have supervised intravenous uses
- Conditions / goals discussed
- Type 1 diabetes · Type 2 diabetes
Insulin medicinesType 1 diabetes / hormone replacement
Provide insulin activity that is missing.
Requires individual training and monitoring. Source ↗
Insulin medicinesType 2 diabetes / selected treatment plans
Supplement insulin when the treatment plan requires it.
Low glucose remains a major safety concern. Source ↗
Health goals & wellness limitsAn anabolic mechanism is not evidence that nonmedical insulin use is a safe muscle-building or anti-ageing practice. The appropriate health-management connection is diabetes education and prevention of hypoglycaemia. [C2]
Read the full guide & references →